Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated December 29, 2020, titled "Glenmark becomes the first company to launch Remogliflozin + Vildagliptin fixed dose combination, at an affordable price for adults with Type 2 Diabetes in India".